Role of the inhibitory quotient in HIV therapy

Antiviral Therapy

Volumn 10, Issue 8, 2005, Pages 879-892

  Hoefnagel, Jolanda G M ^a   Koopmans, Peter P ^a   Burger, David M ^a   Schuurman, Rob ^b   Galama, Jochem M D ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

AMPRENAVIR; AMPRENAVIR PHOSPHATE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ATAZANAVIR; EFAVIRENZ; INDINAVIR; LOPINAVIR; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR;

DRUG BLOOD LEVEL; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PATIENT CARE; PHENOTYPE; PRIORITY JOURNAL; REVIEW; SYSTEMATIC REVIEW; TREATMENT OUTCOME; VIRUS ISOLATION; VIRUS MUTATION; VIRUS RESISTANCE;

ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CLINICAL TRIALS; DRUG RESISTANCE, VIRAL; HIV INFECTIONS; HIV-1; HUMANS; VIRAL LOAD;

EID: 30444452845     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (96)

1. Li TS, Tubiana R, Katlama C, Calvez V, Ait MH & Autran B. Long-lasting recovery in CD4 T-cell function and viral-load reduction after highly active antiretroviral therapy in advanced HIV-1 disease. Lancet 1998; 351:1682-1686.
2. Mocroft A, Vella S, Benfield TL, Chiesi A, Miller V, Gargalianos P, d'Arminio MA, Yust I, Bruun JN, Phillips AN & Lundgren JD. Changing patterns of mortality across Europe in patients infected with HIV-1. EuroSIDA Study Group. Lancet 1998; 352:1725-1730.
3. Novak RM, Chen L, MacArthur RD, Baxter JD, Huppler HK, Peng G, Xiang Y, Henely C, Schmetter B, Uy J, Berg-Wolf M & Kozal M. Prevalence of antiretroviral drug resistance mutations in chronically HIV-infected, treatment-naive patients: implications for routine resistance screening before initiation of antiretroviral therapy. Clinical Infectious Diseases 2005; 40:468-474.
4. DeGruttola V, Dix L, D'Aquila R, Holder D, Phillips A, Ait-Khaled M, Baxter J, Clevenbergh P, Hammer S, Harrigan R, Katzenstein D, Lanier R, Miller M, Para M, Yerly S, Zolopa A, Murray J, Patick A, Miller V, Castillo S, Pedneault L & Mellors J. The relation between baseline HIV drug resistance and response to antiretroviral therapy: re-analysis of retrospective and prospective studies using a standardized data analysis plan. Antiviral Therapy 2000; 5:41-48.
5. Zolopa AR, Shafer RW, Warford A, Montoya JG, Hsu P, Katzenstein D, Merigan TC & Efron B. HIV-1 genotypic resistance patterns predict response to saquinavir-ritonavir therapy in patients in whom previous protease inhibitor therapy had failed. Annals of Internal Medicine 1999; 131:813-821.
6. Baxter JD, Mayers DL, Wentworth DN, Neaton JD, Hoover ML, Winters MA, Mannheimer SB, Thompson MA, Abrams DI, Brizz BJ, Ioannidis JP & Merigan TC. A randomized study of antiretroviral management based on plasma genotypic antiretroviral resistance testing in patients failing therapy. CPCRA 046 Study Team for the Terry Beirn Community Programs for Clinical Research on AIDS. AIDS 2000; 14:83-93.
7. Durant J, Clevenbergh P, Halfon P, Delgiudice P, Porsin S, Simonet P, Montagne N, Boucher CA, Schapiro JM & Dellamonica P. Drug-resistance genotyping in HIV-1 therapy: the VIRADAPT randomised controlled trial. Lancet 1999; 353:2195-2199.
8. Tural C, Ruiz L, Holtzer C, Schapiro J, Viciana P, Gonzalez J, Domingo P, Boucher C, Rey-Joly C & Clotet B. Clinical utility of HIV-1 genotyping and expert advice: the Havana trial. AIDS 2002; 16:209-218.
9. Duval X, Lamotte C, Race E, Descamps D, Damond F, Clavel F, Leport C, Peytavin G & Vilde JL. Amprenavir inhibitory quotient and virological response in human immunodeficiency virus-infected patients on an amprenavir-containing salvage regimen without or with ritonavir. Antimicrobial Agents and Chemotherapy 2002; 46:570-574.
10. Kempf DJ, Isaacson JD, King MS, Brun SC, Sylte J, Richards B, Bernstein B, Rode R & Sun E. Analysis of the virological response with respect to baseline viral phenotype and genotype in protease inhibitor-experienced HIV-1-infected patients receiving lopinavir/ritonavir therapy. Antiviral Therapy 2002; 7:165-174.
11. Mallon PW, Ray J & Cooper DA. Effect of therapeutic drug monitoring on outcome in antiretroviral experienced HIV-infected individuals. Journal of Clinical Virology 2003; 26:223-227.
12. Durant J, Clevenbergh P, Garraffo R, Halfon P, Icard S, Del Giudice P, Montagne N, Schapiro JM & Dellamonica P. Importance of protease inhibitor plasma levels in HIV-infected patients treated with genotypic-guided therapy: pharmacological data from the Viradapt Study. AIDS 2000; 14:1333-1339.
13. Marzolini C, Telenti A, Decosterd LA, Greub G, Biollaz J & Buclin T. Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients. AIDS 2001; 15:71-75.
14. Veldkamp AI, Weverling GJ, Lange JM, Montaner JS, Reiss P, Cooper DA, Vella S, Hall D, Beijnen JH & Hoetelmans RM. High exposure to nevirapine in plasma is associated with an improved virological response in HIV-1-infected individuals. AIDS 2001; 15:1089-1095.
15. Burger DM, Hoetelmans RM, Hugen PW, Mulder JW, Meenhorst PL, Koopmans PP, Brinkman K, Keuter M, Dolmans W & Hekster YA. Low plasma concentrations of indinavir are related to virological treatment failure in HIV-1-infected patients on indinavir-containing triple therapy. Antiviral Therapy 1998; 3:215-220.
16. Acosta EP, Henry K, Baken L, Page LM & Fletcher CV. Indinavir concentrations and antiviral effect. Pharmacotherapy 1999; 19:708-712.
17. Baxter JD, Merigan TC, Wentworth DN, Neaton JD, Hoover ML, Hoetelmans RM, Piscitelli SC, Verbiest WH & Mayers DL. Both baseline HIV-1 drug resistance and antiretroviral drug levels are associated with short-term virologic responses to salvage therapy. AIDS 2002; 16:1131-1138.
18. Gonzalez dR, Gallego O, Valer L, Jimenez-Nacher I & Soriano V. Prediction of virological response to lopinavir/ritonavir using the genotypic inhibitory quotient. AIDS Research and Human Retroviruses 2004; 20:275-278.
19. Marcelin AG, Cohen-Codar I, King MS, Colson P, Guillevic E, Descamps D, Lamotte C, Schneider V, Ritter J, Segondy M, Peigue-Lafeuille H, Morand-Joubert L, Schmuck A, Ruffault A, Palmer P, Chaix ML, Mackiewicz V, Brodard V, Izopet J, Cottalorda J, Kohli E, Chauvin JP, Kempf DJ, Peytavin G & Calvez V. Virological and pharmacological parameters predicting the response to lopinavir-ritonavir in heavily protease inhibitor-experienced patients. Antimicrobial Agents and Chemotherapy 2005; 49:1720-1726.
20. Hsu A, Isaacson J, Brun S, Bernstein B, Lam W, Bertz R, Foit C, Rynkiewicz K, Richards B, King M, Rode R, Kempf DJ, Granneman GR & Sun E. Pharmacokinetic-pharmacodynamic analysis of lopinavir-ritonavir in combination with efavirenz and two nucleoside reverse transcriptase inhibitors in extensively pretreated human immunodeficiency virus-infected patients. Antimicrobial Agents and Chemotherapy 2003; 47:350-359.
21. Hirsch MS, Brun-Vezinet F, Clotet B, Conway B, Kuritzkes DR, D'Aquila RT, Demeter LM, Hammer SM, Johnson VA, Loveday C, Mellors JW, Jacobsen DM & Richman DD. Antiretroviral drug resistance testing in adults infected with human immunodeficiency virus type 1: 2003 recommendations of an International AIDS Society-USA Panel. Clinical Infectious Diseases 2003; 37:113-128.
22. Boucher CA, Keulen W, van Bommel T, Nijhuis M, de Jong D, de Jong MD, Schipper P & Back NK. Human immunodeficiency virus type 1 drug susceptibility determination by using recombinant viruses generated from patient sera tested in a cell-killing assay. Antimicrobial Agents and Chemotherapy 1996; 40:2404-2409.
23. Casado JL, Moreno S, Hertogs K, Dronda F, Antela A, Dehertogh P, Perez-Elias MJ & Moreno A. Plasma drug levels, genotypic resistance, and virological response to a nelfinavir plus saquinavir-containing regimen. AIDS 2002; 16:47-52.
24. Taburet AM, Raguin G, Le Tiec C, Droz C, Barrail A, Vincent I, Morand-Joubert L, Chene G, Clavel F & Girard PM. Interactions between amprenavir and the lopinavir-ritonavir combination in heavily pretreated patients infected with human immunodeficiency virus. Clinical Pharmacology and Therapeutics 2004; 75:310-323.
25. Fletcher CV, Jiang H, Brundage RC, Acosta EP, Haubrich R, Katzenstein D & Gulick RM. Sex-based differences in saquinavir pharmacology and virologic response in AIDS Clinical Trials Group Study 359. The Journal of Infectious Diseases 2004; 189:1176-1184.
26. Parkin NT, Chappey C & Petropoulos CJ. Improving lopinavir genotype algorithm through phenotype correlations: novel mutation patterns and amprenavir cross-resistance. AIDS 2003; 17:955-961.
27. Katzenstein DA, Bosch RJ, Hellmann N, Wang N, Bacheler L & Albrecht MA. Phenotypic susceptibility and virological outcome in nucleoside-experienced patients receiving three or four antiretroviral drugs. AIDS 2003; 17:821-830.
28. Boffito M, Hoggard PG, Lindup WE, Bonora S, Sinicco A, Khoo SH, Di Perri G & Back DJ. Lopinavir protein binding in vivo through the 12-hour dosing interval. Therapeutic Drug Monitoring 2004; 26:35-39.
29. Anderson PL, Brundage RC, Bushman L, Kakuda TN, Remmel RP & Fletcher CV. Indinavir plasma protein binding in HIV-1-infected adults. AIDS 2000; 14:2293-2297.
30. Lazdins JK, Mestan J, Goutte G, Walker MR, Bold G, Capraro HG & Klimkait T. In vitro effect of alpha1-acid glycoprotein on the anti-human immunodeficiency virus (HIV) activity of the protease inhibitor CGP 61755: a comparative study with other relevant HIV protease inhibitors. The Journal of Infectious Diseases 1997; 175:1063-1070.
31. Le Tiec C, Barrail A, Goujard C & Taburet AM. Clinical pharmacokinetics and summary of efficacy and tolerability of atazanavir. Clinical Pharmacokinetics 2005; 44:1035-1050.
32. Hickman D, Vasavanonda S, Nequist G, Colletti L, Kati WM, Bertz R, Hsu A & Kempf DJ. Estimation of serum-free 50-percent inhibitory concentrations for human immunodeficiency virus protease inhibitors lopinavir and ritonavir. Antimicrobial Agents and Chemotherapy 2004; 48:2911-2917.
33. Hsu A, Bertz R, Hickman D, Emery M, Kumar G, Dennison J, Vasavabibda S, Molla A, Kempf D, Granneman GR & Sun E. Assessment of plasma protein binding of lopinavir and ritonavir between in vitro and ex vivo experiments and between HIV-infected patients and HIV-negative healthy volunteers. 8th Conference on Retroviruses and Opportunistic Infections. 4-8 February 2001. Chicago, USA. Abstract 753.
34. Sturmer M, Doerr HW, Staszewski S & Preiser W. Comparison of nine resistance interpretation systems for HIV-1 genotyping. Antiviral Therapy 2003; 8:239-244.
35. Turner D, Schapiro JM, Brenner BG & Wainberg MA. The influence of protease inhibitor resistance profiles on selection of HIV therapy in treatment-naive patients. Antiviral Therapy 2004; 9:301-314.
36. Marcelin AG, Lamotte C, Delaugerre C, Ktorza N, Ait MH, Cacace R, Bonmarchand M, Wirden M, Simon A, Bossi P, Bricaire F, Costagliola D, Katlama C, Peytavin G & Calvez V. Genotypic inhibitory quotient as predictor of virological response to ritonavir-amprenavir in human immunodeficiency virus type 1 protease inhibitor-experienced patients. Antimicrobial Agents and Chemotherapy 2003; 47:594-600.
37. Torti C, Quiros-Roldan E, Keulen W, Scudeller L, Lo CS, Boucher C, Castelli F, Mazzotta F, Pierotti P, Been-Tiktak AM, Buccoliero G, De Gennaro M, Carosi G & Tinelli C. Comparison between rules-based human immunodeficiency virus type 1 genotype interpretations and real or virtual phenotype: concordance analysis and correlation with clinical outcome in heavily treated patients. The Journal of Infectious Diseases 2003; 188:194-201.
38. Valer L, de Mendoza C, De Requena DG, Labarga P, Garcia-Henarejos A, Barreiro P, Guerrero F, Vergara A & Soriano V. Impact of HIV genotyping and drug levels on the response to salvage therapy with saquinavir/ritonavir. AIDS 2002; 16:1964-1966.
39. Valer L, Gonzalez dR, de Mendoza C, Martin-Carbonero L, Gonzalez-Lahoz J & Soriano V. Impact of drug levels and baseline genotype and phenotype on the virologic response to amprenavir/ritonavir-based salvage regimens. AIDS Patient Care STDS 2004; 18:1-6.
40. Larder BA, Kohli A, Kellam P, Kemp SD, Kronick M & Henfrey RD. Quantitative detection of HIV-1 drug resistance mutations by automated DNA sequencing. Nature 1993; 365:671-673.
41. Leitner T, Halapi E, Scarlatti G, Rossi P, Albert J, Fenyo EM & Uhlen M. Analysis of heterogeneous viral populations by direct DNA sequencing. BioTechniques 1993; 15:120-127.
42. Schuurman R, Demeter L, Reichelderfer P, Tijnagel J, de Groot T & Boucher C. Worldwide evaluation of DNA sequencing approaches for identification of drug resistance mutations in the human immunodeficiency virus type 1 reverse transcriptase. Journal of Clinical Microbiology 1999; 37:2291-2296.
43. van Laethem K, Van Vaerenbergh K, Schmit JC, Sprecher S, Hermans P, De VV, Schuurman R, Harrer T, Witvrouw M, Van Wijngaerden E, Stuyver L, Van Ranst M, Desmyter J, De Clercq E & Vandamme AM. Phenotypic assays and sequencing are less sensitive than point mutation assays for detection of resistance in mixed HIV-1 genotypic populations. Journal of Acquired Immune Deficiency Syndromes 1999; 22:107-118.
44. Aberg JA, Gallant JE, Anderson J, Oleske JM, Libman H, Currier JS, Stone VE & Kaplan JE. Primary care guidelines for the management of persons infected with human immunodeficiency virus: recommendations of the HIV Medicine Association of the Infectious Diseases Society of America. Clinical Infectious Diseases 2004; 39:609-629.
45. Perez-Elias MJ, Garcia-Arota I, Munoz V, Santos I, Sanz J, Abraira V, Arribas JR, Gonzalez J, Moreno A, Dronda F, Antela A, Pumares M, Marti-Belda P, Casado JL, Geijos P & Moreno S. Phenotype or virtual phenotype for choosing antiretroviral therapy after failure: a prospective, randomized study. Antiviral Therapy 2003; 8:577-584.
46. Saracino A, Monno L, Locaputo S, Torti C, Scudeller L, Ladisa N, Antinori A, Sighinolfi L, Chirianni A, Mazzotta F, Carosi G & Angarano G. Selection of Antiretroviral Therapy Guided by Genotypic or Phenotypic Resistance Testing: An Open-Label, Randomized, Multicenter Study (PhenGen). Journal of Acquired Immune Deficiency Syndromes 2004; 37:1587-1598.
47. Mazzotta F, Lo-Caputo S, Torti C, Tinelli C, Pierotti P, Castelli F, Lazzarin A, Angarano G, Maserati R, Gianotti N, Ladisa N, Quiros-Roldan E, Rinehart AR & Carosi G. Real versus virtual phenotype to guide treatment in heavily pretreated patients: 48-week follow-up of the Genotipo-Fenotipo di Resistenza (GenPheRex) trial. Journal of Acquired Immune Deficiency Syndromes 2003; 32:268-280.
48. Puchhammer-Stockl E, Steininger C, Geringer E & Heinz FX. Comparison of virtual phenotype and HIV-SEQ program (Stanford) interpretation for predicting drug resistance of HIV strains. HIV Medicine 2002; 3:200-206.
49. Gallego O, Martin-Carbonero L, Aguero J, Mendoza CC, Corral A & Soriano V. Correlation between rules-based interpretation and virtual phenotype interpretation of HIV-1 genotypes for predicting drug resistance in HIV-infected individuals. Journal of Virological Methods 2004; 121:115-118.
50. Aarnoutse RE, Schapiro JM, Boucher CA, Hekster YA & Burger DM. Therapeutic drug monitoring: an aid to optimising response to antiretroviral drugs? Drugs 2003; 63:741-753.
51. Molla A, Korneyeva M, Gao Q, Vasavanonda S, Schipper PJ, Mo HM, Markowitz M, Chernyavskiy T, Niu P, Lyons N, Hsu A, Granneman GR, Ho DD, Boucher CA, Leonard JM, Norbeck DW & Kempf DJ. Ordered accumulation of mutations in HIV protease confers resistance to ritonavir. Nature Medicine 1996; 2:760-766.
52. Schapiro JM, Winters MA, Stewart F, Efron B, Norris J, Kozal MJ & Merigan TC. The effect of high-dose saquinavir on viral load and CD4+ T-cell counts in HIV-infected patients. Annals of Internal Medicine 1996; 124:1039-1050.
53. Burger DM, Aarnoutse RE & Hugen PW. Pros and cons of therapeutic drug monitoring of antiretroviral agents. Current Opinion in Infectious Diseases 2002; 15:17-22.
54. Mouroux M, Yvon-Groussin A, Peytavin G, Delaugerre C, Legrand M, Bossi P, Do B, Trylesinski A, Diquet B, Dohin E, Delfraissy JF, Katlama C & Calvez V. Early virological failure in naive human immunodeficiency virus patients receiving saquinavir (soft gel capsule)-stavudine-zalcitabine (MIKADO trial) is not associated with mutations conferring viral resistance. Journal of Clinical Microbiology 2000; 38:2726-2730.
55. Burger DM, Hugen PW, Aarnoutse RE, Hoetelmans RM, Jambroes M, Nieuwkerk PT, Schreij G, Schneider MM, van der Ende ME & Lange JM. Treatment failure of nelfinavir-containing triple therapy can largely be explained by low nelfinavir plasma concentrations. Therapeutic Drug Monitoring 2003; 25:73-80.
56. Powderly WG. Limitations of current HIV therapies: opportunities for improvement. Journal of Acquired Immune Deficiency Syndromes 2003; 33:7-12.
57. Dumon C, Solas C, Thuret I, Chambost H, Lacarelle B, Michel G & Durand A. Relationship between efficacy, tolerance, and plasma drug concentration of ritonavir in children with advanced HIV infection. Therapeutic Drug Monitoring 2000; 22:402-408.
58. Duong M, Piroth L, Peytavin G, Forte F, Kohli E, Grappin M, Buisson M, Chavanet P & Portier H. Value of patient self-report and plasma human immunodeficiency virus protease inhibitor level as markers of adherence to anti-retroviral therapy: relationship to virologic response. Clinical Infectious Diseases 2001; 33:386-392.
59. Pellegrin I, Breilh D, Montestruc F, Caumont A, Garrigue I, Morlat P, Le Camus C, Saux MC, Fleury HJ & Pellegrin JL. Virologic response to nelfinavir-based regimens: pharmacokinetics and drug resistance mutations (VIRAPHAR study). AIDS 2002; 16:1331-1340.
60. Le Moing V, Peytavin G, Journot V, Cottalorda J, Bouvet E, Chene G, Preau M, de Boever CM, Leport C & Raffi F. Plasma levels of indinavir and nelfinavir at time of virologic response may have a different impact on the risk of further virologic failure in HIV-infected patients. Journal of Acquired Immune Deficiency Syndromes 2003; 34:497-499.
61. Anderson PL, Kakuda TN, Kawle S & Fletcher CV. Antiviral dynamics and sex differences of zidovudine and lamivudine triphosphate concentrations in HIV-infected individuals. AIDS 2003; 17:2159-2168.
62. Fletcher CV, Kawle SP, Kakuda TN, Anderson PL, Weller D, Bushman LR, Brundage RC & Remmel RP. Zidovudine triphosphate and lamivudine triphosphate concentration-response relationships in HIV-infected persons. AIDS 2000; 14:2137-2144.
63. Kakuda TN, Page LM, Anderson PL, Henry K, Schacker TW, Rhame FS, Acosta EP, Brundage RC & Fletcher CV. Pharmacological basis for concentration-controlled therapy with zidovudine, lamivudine, and indinavir. Antimicrobial Agents and Chemotherapy 2001; 45:236-242.
64. Marzolini C, Buclin T, Decosterd LA, Biollaz J & Telenti A. Nelfinavir plasma levels under twice-daily and three-times-daily regimens: high interpatient and low intrapatient variability. Therapeutic Drug Monitoring 2001; 23:394-398.
65. Ghosn J, Lamotte C, Ait-Mohand H, Wirden M, Agher R, Schneider L, Bricaire F, Duvivier C, Calvez V, Peytavin G & Katlama C. Efficacy of a twice-daily antiretroviral regimen containing 100 mg ritonavir/400 mg indinavir in HIV-infected patients. AIDS 2003; 17:209-214.
66. Shulman N, Zolopa A, Havlir D, Hsu A, Renz C, Boller S, Jiang P, Rode R, Gallant J, Race E, Kempf DJ & Sun E. Virtual inhibitory quotient predicts response to ritonavir boosting of indinavir-based therapy in numan immunodeficiency virus-infected patients with ongoing viremia. Antimicrobial Agents and Chemotherapy 2002; 46:3907-3916.
67. Burger DM, Aarnoutse RE, Dieleman JP, Gyssens IC, Nouwen J, de Marie S, Koopmans PP, Stek M, Jr. & van der Ende ME. A once-daily HAART regimen containing indinavir + ritonavir plus one or two nucleoside reverse transcriptase inhibitors (PIPO study). Antiviral Therapy 2003; 8:455-461.
68. De Luca A, Baldini F, Cingolani A, Di Giambenedetto S, Hoetelmans RM & Cauda R. Deep Salvage With Amprenavir and Lopinavir/Ritonavir: Correlation of Pharmacokinetics and Drug Resistance With Pharmacodynamics. Journal of Acquired Immune Deficiency Syndromes 2004; 35:359-366.
69. Breilh D, Pellegrin I, Rouzes A, Berthoin K, Xuereb F, Budzinski H, Munck M, Fleury HJ, Saux MC & Pellegrin JL. Virological, intracellular and plasma pharmacological parameters predicting response to lopinavir/ritonavir (KALEPHAR study). AIDS 2004; 18:1305-1310.
70. Marcelin AG, Dalban C, Peytavin G, Lamotte C, Agher R, Delaugerre C, Wirden M, Conan F, Dantin S, Katlama C, Costagliola D & Calvez V. Clinically relevant interpretation of genotype and relationship to plasma drug concentrations for resistance to saquinavir-ritonavir in human immunodeficiency virus type 1 protease inhibitor-experienced patients. Antimicrobial Agents and Chemotherapy 2004; 48:4687-4692.
71. Ellner PD & Neu HC. The inhibitory quotient. A method for interpreting minimum inhibitory concentration data. The Journal of the American Medical Association 1981; 246:1575-1578.
72. Condra JH, Petropoulos CJ, Ziermann R, Schleif WA, Shivaprakash M & Emini EA. Drug resistance and predicted virologic responses to human immunodeficiency virus type 1 protease inhibitor therapy. The Journal of Infectious Diseases 2000; 182:758-765.
73. trough inhibitory quotient predicts virologic response to ABT-378/ritonavir (ABT-378/r) therapy in treatment-experienced patients. 5th International Congress on Drug Therapy in HIV Infection. 22-26 October 2000, Glasgow, Scotland. Abstract PL9.3.
74. trough/IC50) as predictor of virological response. AIDS 2003; 17:262-264.
75. trough, atazanavir genotypic inhibitory quotient, and baseline HIV genotype as predictors of a 24-week virological response in highly drug-experienced, HIV-infected patients treated with unboosted atazanavir. The New Microbiologica 2005; 28:119-125.
76. Barrios A, Rendon AL, Gallego O, Martin-Carbonero L, Valer L, Rios P, Maida I, Garcia-Benayas T, Jimenez-Nacher I, Gonzalez-Lahoz J St Soriano V. Predictors of virological response to atazanavir in protease inhibitor-experienced patients. HIV Clinical Trials 2004; 5:201-205.
77. Winston A, Hales G, Amin J, van Schaick E, Cooper DA & Emery S. The normalized inhibitory quotient of boosted protease inhibitors is predictive of viral load response in treatment-experienced HIV-1-infected individuals. AIDS 2005; 19:1393-1399.
78. Castagna A, Gianotti N, Galli L, Danise A, Hasson H, Boeri E, Hoetelmans R, Nauwelaers D & Lazzarin A. The NIQ of lopinavir is predictive of a 48-week virological response in highly treatment-experienced HIV-1-infected subjects treated with a lopinavir/ritonavir-containing regimen. Antiviral Therapy 2004; 9:537-543.
79. Raguin G, Chene G, Morand-Joubert L, Taburet AM, Droz C, Le Tiec C, Clavel F & Girard PM. Salvage therapy with amprenavir, lopinavir and ritonavir 200 mg/d or 400 mg/d in HIV-infected patients in virological failure. Antiviral Therapy 2004; 9:615-625.
80. Bertz R, Li J, King M, Kempf DJ, Podzamczer D, Flexner C, Katlama C, Havlir DV, Letendre S, Eron J, Weiss L, Gatell JM, Simon A, Robinson K & Brun S. Lopinavir Inhibitory Quotient predicts virologic response in highly antiretroviral-experienced patients receiving high-dose lopinavir/ritonavir. 11th Conference on Retroviruses and Opportunistic Infections. 8-11 February 2004, San Francisco, California, USA. Abstract 134.
81. Podzamczer D, Tressler R, Flexner C, Katlama C, Havlir D, Letendre S, Eron J, Weiss L, Gatell J, Simon A, Ferrer E, King M, Bertz R, Robinson K & Brun S. Higher doses of lopinavir/ritonavir (LPV/r) in highly treatment-experienced, HIV-infected patients: 48-week safety/efficacy evaluation. 15th International AIDS Conference. 11-16 July 2004. Bangkok, Thailand. Abstract TuPeB4555.
82. Mayers DL, Kohlbrenner VM, Dohnanyil C, Sabo JP, MacGregor TR, Verbiest W, McKenna P & McCallister S. The inhibitory quotient (IQ) of tipranavir/ritonavir (TPV/r) in triple class experienced HIV+ patients; results from BI 1182.52. 2nd IAS Conference on HIV Pathogenesis and Treatment. 13-17 July 2003, Paris, France. Abstract 9.
83. 50 does not predict clinical outcome. 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy. 14-17 September 2003, Chicago, USA. Abstract 1799.
84. Soriano V, Valer L, Gonzalez-de-Requena D, de Mendoza, C & Gonzalez-Lahoz J. Predictive value of drug levels, HIV genotyping, and the Genotypic Inhibitory Quotient (GIQ) at different timepoints along 48 weeks using a saquinavir/ritonavir salvage therapy. 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy. 14-17 September 2003, Chicago, USA. Abstract 1999-2003:
85. Marcelin AG, Lamotte C, Ait-Mohand H, Delaugerre C, Ktorza N, Bossi P, Bricaire F, Costagliola D, Katlama C, Peytavin G & Calvez V. Efficacy of ritonavir/amprenavir containing regimen in HIV-1 protease inhibitor experienced patients and predictivity of the delta viral load values up to week 24 using genotypic inhibitory quotient. 2nd IAS Conference on HIV Pathogenesis and Treatment. 13-17 July 2003, Paris, France. Abstract 165.
86. Marcelin AG, Delaugerre C, Ktorza N, Ait-Mohand H, Wirden M, Simon A, Lamotte C, Bossi P, Bricaire F, Costagliola D, Katlama C, Peytavin G & Calvez V. Genotypic and phenotypic inhibitory quotients as predictors of the virological response to a ritonavir/amprenavir containing regimen in HIV-1 protease inhibitor experienced patients. The 7th International Congress on Drug Therapy in HIV Infection. 14-18 November 2004, Glasgow, Scotland. Abstract PL6.5.
87. Barrail A, Droz C, Morand-Joubert L, Dam E, Le Tiec C, Clavel F, Chene G, Raguin G, Girard P & Taburet A. Inhibitory Quotients as predictors of the virological response to amprenavir in heavily pretreated patients. 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy. 14-17 September 2003, Chicago, USA. Abstract H-1998.
88. Xu F, Tomkins S, Yates P, Richards N, Sharp S, Wire MB, Tisdale M & Elston R. Genotypic inhibitory quotient predicts response to fosamprenavir/ritonavir. 7th International Congress on Drug Therapy in HIV Infection. 14-18 November 2004, Glasgow, Scotland. Abstract P141.
89. Gonzalez-de-Requena D, Gallego O, Valer L, Jimenez-Nacher I & Soriano V. Predictive power of Genotypic Inhibitory Quotient and Lopinavir Plasma levels in both efficacy and lipid elevations of LPV/r-based salvage regimens at 48 weeks. 11th Conference on Retroviruses and Opportunistic Infections. 8-11 February 2004, San Francisco, California, USA. Abstract 610.
90. Cabie A, Lamotte C, Dos Santos G, Pay SM, Abel S, Ouka M, Cesaire R, Liautaud B & Peytavin G. Therapeutic Drug Monitoring (TDM) of lopinavir/ritonavir (LPV/r) combination in Caribbean HIV infected patients. 15th International AIDS Conference. 11-16 July 2004, Bangkok, Thailand. Abstract 4722.
91. Isaacson J, Kempf D, Calvez V, Cohen-Codar I, Descamps D, Guillevic E, Bernstein B, Sun E, Chauvin JP & Rode R. Quantitative estimate of the effect of individual baseline mutations in HIV protease on the virologic response to Eopinavir/Ritonavir therapy in heavily antiretroviral-experienced patients. 9th Conference on Retroviruses and Opportunistic Infections. 24-28 February 2002, Seattle, Washington, USA. Abstract 559.
92. trough, genotype and GIQ as predictors of a 24-week virological response in highly experienced patients treated with unboosted ATV. 7th International Congress on Drug Therapy in HIV Infection. 14-18 November 2004, Glasgow, Scotland. Abstract P116.
93. trough is associated with efficacy and safety: definition of therapeutic range. 12th Conference on Retroviruses and Opportunistic Infections. 22-25 February 2005, Boston, Massachusetts, USA. Abstract 645.
94. Mallolas J, Blanco JL, Labarga P, Vergara A, Ocampo A, Sarasa M, Arnedo M, Lopez-Pua Y, Garcia J, Juega J, Guelar A, Terron A, Dalmau D, Garcia I, Zarraga M, Martinez E, Carne X, Pumarola T & Gatell JM. Inhibitory quotient (IQ) of saquinavir as prognostic factor of response to salvage antiretroviral therapy. 15th International AIDS Conference. 11-16 July 2004, Bangkok, Thailand. Abstract 4655.
95. Birk M, Svedhem V & Sonnerborg A. Kinetics of HIV-1 RNA and resistance-associated mutations after cessation of antiretroviral combination therapy. AIDS 2001; 15:1359-1368.
96. Bertz R, Rode R, Vrijens B, Foit C, Zhu T, Tousset E, Robinson K & Brun S. Adherence in combination with Lopinavir Inhibitory Quotient (IQ) and number of active antiretrovirals (ARVs) predicts virologic response in highly ARV-experienced patients receiving high-dose Lopinavir/ritonavir (LPV/r). 7th International Congress on Drug Therapy in HIV Infection. 14-18 November 2004, Glasgow, Scotland. Abstract P91.